Menu

Pioneering Heart Transplant Program Suspended

The move by Baylor St. Luke’s Medical Center follows an investigative news report detailing surgical errors and poor research practices.

Jun 4, 2018
Kerry Grens

ISTOCK, BARANOZDEMIRBaylor St. Luke’s Medical Center in Houston, a leading heart transplant center, has suspended its transplant program for two weeks, ProPublica and The Houston Chronicle reported jointly on Friday (June 1). The pause in operations comes within weeks of a damning investigative report by the two news outlets revealing extensive troubles with patient outcomes and research misconduct.

“I’m glad they are doing something,” Jennifer Lewis, whose husband died after a heart transplant and numerous follow-up surgeries at St. Luke’s, tells ProPublica and The Houston Chronicle. “That was my hope in speaking out and telling Lee’s story.”

In the case of Lewis’s husband, a mechanical failure in the operating room left the surgeon needing to hand-pump the patient’s newly transplanted heart for 10 minutes. A back-up defibrillator to jump-start the heart was not placed nearby, according to the surgeon, likely causing damage to the organ. The situation serves as an example of the transplant surgery performance at St. Luke’s in recent years: once a pioneering facility when transplants were first becoming available in the 1960s, it now ranks near the bottom in patient outcomes. “[T]wice as many St. Luke’s patients died within a year as would have been expected, taking into account patient characteristics and illnesses,” the news outlets state.

“Although extensive reviews are conducted on each unsuccessful transplant, the recent patient outcomes deserve an in-depth review before we move forward with the program,” Doug Lawson, CEO of the organization that owns St. Luke’s, says in a statement, according to ProPublica and The Houston Chronicle. “Our prayers are with the families, as well as all those on the waiting list.”

The journalists’ investigation also unearthed reports of research malpractice by one of the world’s leading developers of artificial hearts, Bud Frazier. A decade ago, St. Luke’s found that Frazier was implanting experimental devices into patients who didn’t qualify medically. The hospital had to repay millions of dollars of research funds to the U.S. government; none of this had been previously disclosed to the public.

Frazier is also accused of not disclosing conflicts of interest and failing to report problems with experimental heart pumps. “In the old days of medicine . . . that’s the way these guys did things,” Frank Smart, who worked with Frazier at Texas Heart, an affiliate of St. Luke’s, and who is now the chief of cardiology at Louisiana State University School of Medicine, tells ProPublica and The Houston Chronicle. “It was, ‘Well, I have an idea, and I’m the one that knows best, and by golly, I’m going to do it.’ And did that advance the field? Maybe. Is it the right thing to do? Absolutely not.”

See “If It Ain’t Broke . . .

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.